#1 Clinical Trials Search in Europe

Emraclidine

Emraclidine is an investigational drug currently being studied in various clinical trials. These trials aim to evaluate its safety, effectiveness, and how it behaves in the human body. The studies are exploring Emraclidine’s potential use in treating conditions like Alzheimer’s disease, while also examining how factors like food, other medications, and health conditions may affect how the body processes the drug.

Table of Contents

What is Emraclidine?

Emraclidine, also known as CVL-231 or PF-06852231, is a new drug currently being studied in clinical trials[1][2]. It is being developed as an oral medication, typically in the form of tablets[3]. Emraclidine is not yet approved for use and is still in the research phase to determine its effectiveness and safety.

Potential Uses of Emraclidine

While the exact uses of Emraclidine are still being investigated, current clinical trials suggest it may have potential applications in the following areas:

  • Alzheimer’s Disease: One study is evaluating the safety and tolerability of Emraclidine in participants with dementia due to Alzheimer’s disease[5]. This suggests that the drug may have potential benefits for cognitive disorders.
  • Other Neurological Conditions: The focus on neurological examinations in several trials indicates that Emraclidine might be developed for various neurological conditions[1][2].

It’s important to note that these potential uses are still under investigation, and more research is needed to confirm the effectiveness of Emraclidine for any specific condition.

How Emraclidine Works

The exact mechanism of action of Emraclidine is not explicitly stated in the available clinical trial information. However, based on the types of studies being conducted, we can infer that it likely works in the following ways:

  • Absorption and Distribution: The drug is taken orally and absorbed into the bloodstream. Several studies are examining how food affects its absorption[1].
  • Metabolism: Emraclidine is processed by the body into at least one known metabolite called CV-0000364[2]. A metabolite is a substance produced when the body breaks down a drug.
  • Elimination: The drug and its metabolites are eliminated from the body through urine and feces[2].

The specific effects of Emraclidine on the brain or other organs are not yet clear from the available information.

Current Clinical Trials

Emraclidine is currently undergoing several Phase 1 clinical trials. Phase 1 trials are early-stage studies primarily focused on understanding how a drug behaves in the human body and assessing its safety. Some key aspects of these trials include:

  • Pharmacokinetics: Many studies are looking at how Emraclidine is absorbed, distributed, metabolized, and eliminated by the body[1][2]. This helps researchers understand how the drug moves through the body over time.
  • Food Effects: One study is specifically examining how food intake affects the absorption and processing of Emraclidine[1].
  • Special Populations: Separate studies are evaluating how Emraclidine behaves in people with liver or kidney impairment[3][4]. This is important because many drugs are processed differently in people with these conditions.
  • Elderly and Alzheimer’s Patients: One trial is looking at the safety and effects of Emraclidine in healthy elderly participants and those with Alzheimer’s disease[5].
  • Drug Interactions: Some studies are investigating how Emraclidine interacts with other medications[6][7].

Safety and Side Effects

As Emraclidine is still in clinical trials, its full safety profile is not yet established. However, the trials are closely monitoring for potential side effects and safety concerns, including:

  • Adverse Events: All trials are tracking any unexpected medical occurrences in participants taking Emraclidine[1][2].
  • Vital Signs: Changes in heart rate, blood pressure, and other vital signs are being monitored[1].
  • ECG Changes: Effects on heart rhythm are being assessed through electrocardiogram (ECG) measurements[1].
  • Laboratory Tests: Blood and other laboratory tests are being conducted to check for any effects on various body systems[1].
  • Neurological Effects: Given the potential neurological applications, special attention is being paid to any neurological changes[1].
  • Suicidality: Changes in suicidal thoughts or behaviors are being monitored using the Columbia Suicide Severity Rating Scale (C-SSRS)[1].
  • Movement Disorders: Some trials are specifically looking for signs of movement disorders, which can be a side effect of some neurological medications[5].

Drug Interactions

Understanding how Emraclidine interacts with other medications is an important part of the ongoing research. Some specific drug interactions being studied include:

  • Itraconazole: This is an antifungal medication. The study is looking at how it affects the processing of Emraclidine in the body[6].
  • Carbamazepine: This is an anticonvulsant and mood-stabilizing drug. Its effects on Emraclidine are being investigated[6].
  • Metformin: This is a common diabetes medication. The study is examining how Emraclidine might affect the processing of metformin[6].
  • Esomeprazole: This is a medication that reduces stomach acid. The study is looking at how it might affect the absorption of Emraclidine[7].

Special Populations

Clinical trials are also investigating how Emraclidine behaves in specific groups of people:

  • Liver Impairment: A study is examining how mild, moderate, and severe liver impairment affects the processing of Emraclidine[3]. This is important because many drugs are metabolized by the liver.
  • Kidney Impairment: Another study is looking at how various degrees of kidney impairment impact Emraclidine’s behavior in the body[4]. This is crucial as the kidneys play a key role in eliminating many drugs from the body.
  • Elderly Individuals: The effects and safety of Emraclidine in older adults are being specifically studied[5].
  • Alzheimer’s Disease Patients: The same study is also examining how people with Alzheimer’s disease respond to Emraclidine[5].

These studies in special populations help ensure that if Emraclidine is eventually approved for use, doctors will know how to adjust dosing or monitoring for different groups of patients.

Aspect Details
Drug Name Emraclidine (also known as CVL-231, PF-06852231)
Administration Oral tablets
Study Types Phase 1 clinical trials
Main Study Objectives Pharmacokinetics, safety, tolerability, drug interactions, effects of food and health conditions
Participant Types Healthy adults, elderly participants, participants with Alzheimer’s disease dementia
Key Measurements Plasma concentration, adverse events, vital signs, laboratory assessments, ECG parameters
Special Considerations Effects of liver impairment, kidney impairment, food intake, and drug interactions

FAQ

  • What is Emraclidine? Emraclidine is an investigational drug being studied in clinical trials. It's also known by other names like CVL-231 and PF-06852231. The exact use of Emraclidine is still being determined through these studies.
  • What conditions is Emraclidine being studied for? While the specific conditions are still being investigated, some trials are studying Emraclidine in participants with dementia due to Alzheimer's disease. However, many of the trials are focused on understanding how the drug works in healthy participants.
  • How is Emraclidine administered? In the clinical trials, Emraclidine is typically given as oral tablets. The dosage and frequency can vary depending on the specific study.
  • What are some of the main things being studied about Emraclidine? The trials are looking at various aspects of Emraclidine, including its safety, how the body processes it (pharmacokinetics), how it interacts with food and other drugs, and how conditions like liver or kidney problems might affect its processing in the body.
  • Are there any known side effects of Emraclidine? The trials are actively monitoring for potential side effects, which is a key part of determining the drug's safety profile. Participants are being closely observed for any adverse events, changes in vital signs, laboratory values, and other health indicators. However, as the drug is still in the investigational stage, a comprehensive list of side effects is not yet established.

Ongoing Clinical Trials on Emraclidine

  • Long-term Safety Study of Emraclidine for Adults with Schizophrenia

    Not recruiting

    1 1
    Investigated drugs:
    Bulgaria Hungary

Glossary

  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and is able to have an active effect.
  • Adverse Event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Placebo: A substance or treatment with no active therapeutic effect, used as a control in testing new drugs.
  • Dementia: A general term for a decline in mental ability severe enough to interfere with daily life.
  • Alzheimer's Disease: A progressive brain disorder that slowly destroys memory and thinking skills.
  • Metabolite: A substance formed in or necessary for metabolism, often referring to the breakdown products of a drug in the body.
  • Cytochrome P450 (CYP): A family of enzymes involved in drug metabolism in the body.
  • Drug-Drug Interaction: A change in a drug's effect on the body when taken with another drug.
  • Immediate Release (IR): A type of drug formulation designed to release the active ingredient quickly after administration.

References

  1. https://clinicaltrials.gov/study/NCT05915546
  2. https://clinicaltrials.gov/study/NCT06301971
  3. https://clinicaltrials.gov/study/NCT05935033
  4. https://clinicaltrials.gov/study/NCT05940402
  5. https://clinicaltrials.gov/study/NCT05644977
  6. https://clinicaltrials.gov/study/NCT05965219
  7. https://clinicaltrials.gov/study/NCT06366243